Golden
Alexandria Venture Investments

Alexandria Venture Investments

Alexandria Venture Investments is venture capital firm operating as a private equity firm.

Company Overview

Alexandria Venture Investments operates as a private equity firm. The Company focuses on commercial and residential properties. Alexandria Venture Investments serves clients in the United States.

History

Founded in 1996, Alexandria Venture Investments is a corporate venture arm of Alexandria Real Estate Equities.

The firm invests in seed and early-stage businesses operating in the life science, healthcare, food, agriculture, and biotechnology sectors.



Alexandria Venture Investments, the strategic investment arm of Alexandria Center® at Kendall Square, is involved in innovation and entrepreneurship by investing capital in diverse science and technology sectors.The firm provides strategic investment capital to innovative life science and technology entities developing breakthrough therapies and technologies.

Investments

Alongside commercial and residential properties, Alexandria also focuses on biotechnology investments.

Alexandria Venture Investments has made over 50 investments. A large investment was made on Jan 30, 2019, when they invested $60M in Dewpoint Therapeutics.



Alexandria Venture Investments has had 7 exits. Alexandria Venture Investments's most notable exits include TCR2, Moderna Therapeutics, and Gritstone Oncology.

Timeline

February 14, 2019

Obsidian Therapeutics

Obsidian Therapeutics

$49,500,000

VENTURE CAPITAL (SERIES A)

February 14, 2019

TCR2 Therapeutics Inc.

$125,000,000

VENTURE CAPITAL (SERIES B)

January 7, 2019

GreenLight Bio

$50,000,000

VENTURE CAPITAL (SERIES E)

January 3, 2019

Immusoft Corporation

$20,000,000

VENTURE CAPITAL (SERIES B)

October 9, 2018

Gotham Therapeutics

$54,000,000

VENTURE CAPITAL (SERIES A)

September 10, 2018

OncoResponse

$40,000,000

VENTURE CAPITAL (SERIES B)

September 9, 2018

Benson Hill Biosystems

$60,000,000

VENTURE CAPITAL (SERIES C)

August 8, 2018

Inari

$40,000,000

VENTURE CAPITAL (SERIES B)

July 11, 2018

Compass Therapeutics

$127,500,000

VENTURE CAPITAL (SERIES A)

July 11, 2018

ORIG3N

VENTURE CAPITAL (SERIES B)

June 26, 2018

Cibus Global, Ltd.

$70,000,000

VENTURE CAPITAL (SERIES C)

June 25, 2018

Skyhawk Therapeutics

$40,000,000

VENTURE CAPITAL

June 12, 2018

StrideBio, LLC

$15,700,000

VENTURE CAPITAL (SERIES A)

May 15, 2018

Nohla Therapeutics

$45,000,000

VENTURE CAPITAL (SERIES B)

May 14, 2018

Celsius Therapeutics

$65,000,000

VENTURE CAPITAL (SERIES A)

April 4, 2018

QurAlis

SEED FUND

March 14, 2018

IDEAYA Biosciences

$94,000,000

VENTURE CAPITAL (SERIES B)

March 7, 2018

Prevail Therapeutics

$75,000,000

VENTURE CAPITAL (SERIES A)

February 26, 2018

Quentis Therapeutics

$48,000,000

VENTURE CAPITAL (SERIES A)

February 21, 2018

Kallyope

$66,000,000

VENTURE CAPITAL (SERIES B)

January 31, 2018

Moderna Therapeutics

$500,000,000

VENTURE CAPITAL (SERIES G)

January 22, 2018

Skyhawk Therapeutics

$8,000,000

SEED FUND

December 6, 2017

Metacrine

$22,000,000

VENTURE CAPITAL (SERIES B)

October 30, 2017

Ribometrix

$7,500,000

SEED FUND

October 16, 2017

Cydan

$34,000,000

VENTURE CAPITAL

September 16, 2017

LifeMine Therapeutics

$55,000,000

VENTURE CAPITAL (SERIES A)

July 31, 2017

Homology Medicines

$83,500,000

VENTURE CAPITAL (SERIES B)

July 24, 2017

Rodeo Therapeutics

$5,900,000

VENTURE CAPITAL (SERIES A)

July 23, 2017

Effector Therapeutics

$38,600,000

VENTURE CAPITAL (SERIES C)

July 10, 2017

Evelo Biosciences

$50,000,000

VENTURE CAPITAL (SERIES B)

April 25, 2017

Arsanis

$45,500,000

VENTURE CAPITAL (SERIES D)

March 27, 2017

Antiva Biosciences

$22,000,000

VENTURE CAPITAL (SERIES C)

March 15, 2017

eGenesis

$38,000,000

VENTURE CAPITAL (SERIES A)

March 1, 2017

Boragen

$10,000,000

VENTURE CAPITAL (SERIES A)

January 30, 2017

Kinestral Technologies, Inc.

$65,000,000

VENTURE CAPITAL (SERIES C)

February 3, 2016

EpiBiome

$6,000,000

VENTURE CAPITAL (SERIES A)

January 25, 2016

Codiak Biosciences

$61,000,000

VENTURE CAPITAL (SERIES B)

January 5, 2016

NextCure

$67,000,000

VENTURE CAPITAL (SERIES A)

January 5, 2016

Petra Pharma

$48,000,000

VENTURE CAPITAL (SERIES A)

People

Name
Role
Related Golden topics

Ambassador James P. Cain

Independent Director



Catherine Nuccio

Associate



Daniel J. Ryan

Co-Chief Investment Officer & Regional Market Director –

San Diego



Dean A. Shigenaga

Co-President &

Chief Financial Officer



James H. Richardson

Senior Management Consultant & Director



Jennifer J. Banks

Co-Chief Operating Officer, General Counsel &

Corporate Secretary



Joel S. Marcus

Executive Chairman & Founder



John H. Cunningham

Executive Vice President, Regional Market Director – New York City



John L. Atkins, III

Independent Director



Lawrence J. Diamond

Co-Chief Operating Officer & Regional Market Director – Maryland



Maria C. Freire

Independent Director



Michael A. Woronoff

Independent Director



Peter M. Moglia

Co-Chief Executive Officer & Co-Chief Investment Officer



Richard H. Klein

Independent Director



Stephen A. Richardson

Co-Chief Executive Officer



Steven Robert Hash

Lead Independent Director



Thomas J. Andrews

Co-President &

Regional Market Director –

Greater Boston



Vincent R. Ciruzzi

Chief Development

Officer



Further reading

Title
Author
Link
Type
Date

Alexandria (ARE) Expands Alexandria LaunchLabs in Cambridge

Zacks Investment Research

Web



Alexandria Real Estate Equities: Is This Stock a Buy? -- The Motley Fool

Todd Campbell

Web



Alexandria Venture Investments Launches the Alexandria Seed Capital Platform, a Novel and Innovative Seed-Stage Life Science Funding Model and a Natural Extension of Alexandria LaunchLabs

Alexandria Real Estate Equities, Inc.

Web



Alexandria Venture Investments Recognized as #1 Most Active Investor in Healthcare Startups

Alexandria Real Estate Equities, Inc.

Web



Backed by Leading Life Science Investors | Cydan



Web



Big VC Backing Gets Behind Biotech's Portfolio of Small Molecule Drugs

Sarah de Crescenzo

Web



Expansion Therapeutics gets $55.3 million funding to back rare disease

The Pharma Letter

Web



Hillhouse, Quan lead $93m Series B for US biopharma firm NextCure

Chalida Ekvitthayavechnukul



Web



Investors - Imara



Web



Investors -- Gotham Therapeutics



Web



Pasadena Now » Pasadena's Alexandria Venture Investments Recognized as #1 Most Active Investor in Healthcare Startups | Pasadena California, Hotels,CA Real Estate,Restaurants,City Guide... - Pasadena.com



Web



Documentaries, videos and podcasts

Title
Date
Link

Alexandria Real Estate Equities Notes "Five Fundamental Pillars" Positive for Life Science Industry



Jenna Foger, Senior Principal, Science & Technology at Alexandria Venture Investments

Oct 28, 2017

Panel Discussion: The Anatomy of a New York City Life Science Startup

21 July 2017

Top VC deals: SurveyMonkey goes public, SoftBank leads three massive rounds

28 September 2018

Companies

Company
CEO
Location
Products/Services







Agtech Accelerator







Antiva Biosciences Inc







Arsanis



















Codiak Biosciences







Compass Therapeutics Llc













Dewpoint Therapeutics































Expansion Therapeutics







Forge Therapeutics Inc







Gotham Therapeutics







Gritstone Oncology



















Ideaya Biosciences







Imara







SHOW ALL (52)

References